Chronic Obstructive Pulmonary Disease and Allied Conditions Clinical Trial
Official title:
Effects of ROFLUMILAST on Markers of Subclinical Atherosclerosis In Stable COPD; the ELASTIC-trial
Chronic obstructive pulmonary disease is associated with a low grade systemic inflammatory
process. Systemic inflammation is hypothesized to maintain cardiovascular morbidity and
mortality in COPD. Early changes of vascular integrity can be detected via markers of
subclinical atherosclerosis.
Selective Inhibition of phosphodiesterase subtype 4 describes a promising therapeutic option
in COPD with beneficial impact on lung function and exacerbation rate. Moreover, an
anti-inflammatory effect of phosphodiesterase-4 inhibition was confirmed by recent data.
The aim of this study is to assess the effects of the phosphodiesterase-4 inhibitor
Roflumilast on firstly surrogates of subclinical atherosclerosis and secondly markers of
systemic inflammation in the peripheral circulation of patients with stable chronic
obstructive pulmonary disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02571582 -
Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy
|
N/A | |
| Completed |
NCT02261337 -
Is Gait Speed and Sarcopenia Prognostic in Chronic Respiratory Disease?
|